ArticleJournal of neurovirology2017
Fatal ruxolitinib-related JC virus meningitis.
Article in Journal of neurovirology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Genetic Diversity of the Polyomavirus JC and Implications for the Pathogenesis of Progressive Multifocal Leukoencephalopathy.Viruses · 2026Review
- JC Polyomavirus Infection: A Narrative Review.Infectious diseases and therapy · 2025Review
- Successful Recovery from Meningoencephalitis Associated with Archetype-like JC Virus in a Lung Transplant Recipient: Case Report and Review of the Literature.Annals of clinical case reports · 2025Article
- Polyomavirus Wakes Up and Chooses Neurovirulence.Viruses · 2023Review
- JAK Inhibition in Juvenile Idiopathic Arthritis (JIA): Better Understanding of a Promising Therapy for Refractory Cases.Journal of clinical medicine · 2023Review
- Review
- Ocular Toxicity of Targeted Anticancer Agents.Drugs · 2021Review
- Cryptococcal fungemia and Mycobacterium haemophilum cellulitis in a patient receiving ruxolitinib: a case report and literature review.BMC infectious diseases · 2021Review
- Emerging Place of JAK Inhibitors in the Treatment of Inborn Errors of Immunity.Frontiers in immunology · 2021Review
- JC virus granule cell neuronopathy associated with Ruxolitinib: A case report and review of the literature.eNeurologicalSci · 2020Article
- The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.Cytokine & growth factor reviews · 2020Review
- Fatal encephalopathy with wild-type JC virus and ruxolitinib therapy.Annals of neurology · 2019Article
- JC virus infection of meningeal and choroid plexus cells in patients with progressive multifocal leukoencephalopathy.Journal of neurovirology · 2019Article
- Persistent polyomavirus-associated nephropathy in a patient with GvHD and treatment with the JAK1/2 inhibitor ruxolitinib.Bone marrow transplantation · 2019Article
- Susceptibility of Primary Human Choroid Plexus Epithelial Cells and Meningeal Cells to Infection by JC Virus.Journal of virology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a possible association between ruxolitinib and JC virus meningitis. A 72-year-old man with myelofibrosis started treatment with ruxolitinib. Fourteen days later, the patient presented to the emergency department with fever and nausea. HIV test was negative. Ruxolitinib was suspended. Symptoms progressed with neck stiffness, cognitive impairment, and motor aphasia. CSF was positive for JC virus. MRI showed nonspecific abnormal findings. Five days after the clinical debut, the patient died. The clinical picture, MRI imaging, and positive JC virus PCR in CSF strongly suggest ruxolitinib-related JC virus meningitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.